BOCA RATON, Fla., May 27, 2011 /PRNewswire/ -- Vicor Technologies, Inc. (OTCBB: VCRT) today announced that CEO David H. Fater will present at RetailInvestorConferences.com. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic used to risk stratify specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention. DATE:
June 2, 2011TIME:
www.retailinvestorconferences.com > red "register/ watch event now" buttonThis will be a live, interactive, online event during which investors are invited to ask the company questions in real-time, both in the presentation hall and at Vicor's "virtual trade booth." For those unable to join the live event, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register to save time and receive event updates.
About RetailInvestorConferences.comRetailInvestorConferences.com, created by BetterInvesting (NAIC), PR Newswire, and MUNCmedia is the first monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with retail investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Retail Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network, and MUNCmedia's sophisticated retail investor targeting.
About Vicor Technologies, Inc.Vicor Technologies' PD2i Analyzer™ employs its patented, proprietary point correlation dimension algorithm (PD2i®), a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. Vicor anticipates use of its PD2i Analyzer™ to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.
|SOURCE Vicor Technologies, Inc.|
Copyright©2010 PR Newswire.
All rights reserved